Robin LaChapelle - 30 Oct 2026 Form 4 Insider Report for ArriVent BioPharma, Inc. (AVBP)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
02 Nov 2026, 16:47:35 UTC
Prior SEC filing
04 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ James Kastenmayer, Attorney-in-Fact for Robin LaChapelle
Filing notes and source

Key filing fact

Robin LaChapelle filed Form 4 for ArriVent BioPharma, Inc. (AVBP) on 02 Nov 2026.

Key facts

  • This page summarizes Robin LaChapelle's Form 4 filing for ArriVent BioPharma, Inc. (AVBP).
  • 10 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 02 Nov 2026, 16:47.

Change

  • Previous filing in this sequence was filed on 04 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002009136 Primary reporting owner

LaChapelle Robin

Relationship
Chief Operating Officer
Address
7325 BELLE MEADE BLVD, MIAMI
Signature
/s/ James Kastenmayer, Attorney-in-Fact for Robin LaChapelle
Signature date
02 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVBP transaction

Common Stock

Options Exercise

Transaction value
Shares
+16,265
Change %
+12%
Price
$3.65*
Shares after
152,001
Date
30 Oct 2026
Ownership
Direct
AVBP transaction

Common Stock

Options Exercise

Transaction value
Shares
+410
Change %
+0.27%
Price
$2.28*
Shares after
152,411
Date
30 Oct 2026
Ownership
Direct
AVBP transaction

Common Stock

Options Exercise

Transaction value
Shares
+4,550
Change %
+3%
Price
$2.28*
Shares after
156,961
Date
30 Oct 2026
Ownership
Direct
AVBP transaction

Common Stock

Options Exercise

Transaction value
Shares
+1,820
Change %
+1.2%
Price
$2.28*
Shares after
158,781
Date
30 Oct 2026
Ownership
Direct
AVBP transaction

Common Stock

Options Exercise

Transaction value
Shares
+17,648
Change %
+11%
Price
$6.24*
Shares after
176,429
Date
30 Oct 2026
Ownership
Direct
AVBP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
394,477
Date
30 Oct 2026
Ownership
by Trust
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVBP transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-410
Change %
-100%
Price
$0.000000*
Shares after
0
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
410
Exercise price
$2.28
Footnotes
F2, F3
AVBP transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-4,550
Change %
-71%
Price
$0.000000*
Shares after
1,820
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,550
Exercise price
$2.28
Footnotes
F2, F4
AVBP transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-1,820
Change %
-100%
Price
$0.000000*
Shares after
0
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,820
Exercise price
$2.28
Footnotes
F2, F4
AVBP transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-16,265
Change %
-86%
Price
$0.000000*
Shares after
2,600
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
16,265
Exercise price
$3.65
Footnotes
F2, F5
AVBP transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-17,648
Change %
-31%
Price
$0.000000*
Shares after
38,823
Date
30 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
17,648
Exercise price
$6.24
Footnotes
F2, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The Reporting Person is the Trustee of The MAKS Yao Trust and may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust. The Reporting Person does not have a pecuniary interest in and disclaims beneficial ownership of the shares held by The MAKS Yao Trust.

Footnote F2

Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 15.21 and (ii) the exercise price of the option was multiplied by 15.21.

Footnote F3

The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F4

The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F5

The shares underlying this option vested as to 25% on February 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F6

The shares underlying this option vested as to 25% on August 22, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .